Mangoceuticals, Common Stock Stock Current Asset
| MGRX Stock | 4.35 0.08 1.87% |
Mangoceuticals, Common Stock fundamentals help investors to digest information that contributes to Mangoceuticals, Common's financial success or failures. It also enables traders to predict the movement of Mangoceuticals, Stock. The fundamental analysis module provides a way to measure Mangoceuticals, Common's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mangoceuticals, Common stock.
Non Current Assets Total is likely to drop to about 198.4 K in 2025. Total Current Assets is likely to drop to about 563.1 K in 2025. Mangoceuticals, | Current Asset |
Mangoceuticals, Common Stock Company Current Asset Analysis
Mangoceuticals, Common's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Mangoceuticals, Current Asset Historical Pattern
Today, most investors in Mangoceuticals, Common Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mangoceuticals, Common's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Mangoceuticals, Common current asset as a starting point in their analysis.
Mangoceuticals, Common Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Mangoceuticals, Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Mangoceuticals, Common Stock has a Current Asset of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and about the same as Health Care (which currently averages 0.0) industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Mangoceuticals, Common ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mangoceuticals, Common's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mangoceuticals, Common's managers, analysts, and investors.Environmental | Governance | Social |
Mangoceuticals, Fundamentals
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.62 | ||||
| Operating Margin | (11.27) % | ||||
| Current Valuation | 21.41 M | ||||
| Shares Outstanding | 4.97 M | ||||
| Shares Owned By Insiders | 37.13 % | ||||
| Shares Owned By Institutions | 1.86 % | ||||
| Number Of Shares Shorted | 71.47 K | ||||
| Price To Book | 1.58 X | ||||
| Price To Sales | 28.10 X | ||||
| Revenue | 731.49 K | ||||
| Gross Profit | 442.44 K | ||||
| EBITDA | (9.19 M) | ||||
| Net Income | (9.21 M) | ||||
| Total Debt | 128.68 K | ||||
| Book Value Per Share | 6.27 X | ||||
| Cash Flow From Operations | (7 M) | ||||
| Short Ratio | 0.41 X | ||||
| Earnings Per Share | (5.70) X | ||||
| Market Capitalization | 21.22 M | ||||
| Total Asset | 1.05 M | ||||
| Retained Earnings | (11.23 M) | ||||
| Working Capital | 607.38 K | ||||
| Net Asset | 1.05 M |
About Mangoceuticals, Common Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mangoceuticals, Common Stock's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mangoceuticals, Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mangoceuticals, Common Stock based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.